金融界消息 截至2025年8月25日收盘，奥浦迈（688293）报收于58.27元，上涨4.93%，换手率3.59%， 成交量2.78万手，成交金额1.62亿元。 天眼查商业履历信息显示，上海奥浦迈生物科技股份有限公司，成立于2013年，位于上海市，是一家以 从事研究和试验发展为主的企业。企业注册资本11354.8754万人民币，实缴资本6000万人民币。公司法 定代表人为肖志华。 通过天眼查大数据分析，上海奥浦迈生物科技股份有限公司共对外投资了8家企业，参与招投标项目35 次，知识产权方面有商标信息71条，专利信息104条，此外企业还拥有行政许可65个。 来源：金融界 资金流向方面，今日主力资金净流出2653.78万元，占比成交额16.38%。其中，超大单净流出873.70万 元、占成交额5.39%，大单净流出1780.08万元、占成交额10.99%，中单净流出流入1340.91万元、占成 交额8.28%，小单净流入1312.88万元、占成交额8.1%。 奥浦迈最新一期业绩显示，截至2025中报，公司营业总收入1.78亿元、同比增长23.77%，归属净利润 3754.69万元，同比增长55.55%，扣非净利 ...

Core Viewpoint - The research conducted by teams from Shanghai Jiao Tong University and Naval Medical University focuses on developing an engineered epoxidase that significantly simplifies the synthesis of meroterpenoids by enhancing the asymmetric epoxidation of farnesol [3][4]. Group 1: Research Development - The study published in the journal Science introduces a novel strategy that integrates enzyme catalysis with classical synthetic chemistry to construct meroterpenoids [3]. - The research team utilized directed evolution technology to engineer an epoxidase that exhibits unique selectivity for the internal olefin sites of farnesol [4]. Group 2: Synthesis Efficiency - The engineered epoxidase catalyzes the epoxidation reaction with high regioselectivity and enantioselectivity, leading to the production of epoxide intermediates [4]. - This method has successfully simplified the synthetic pathways for various meroterpenoids, reducing the total synthesis steps by more than 50% in most cases [4].

在抗体药研发中，DMPK（药物代谢与药代动力学）研究对于理解药物在体内的行为至关重要。观察抗 体药物在动物组织水平的摄取、定位及动态过程，是评估其靶向递送效率、脱靶蓄积风险及药效/毒性 机制的关键环节，连接着体外数据和临床转化。传统的同位素标记法（如1?C/3H）因需放射性设施， 且成本高、存在辐射风险等问题，不适合抗体药体内的早期快速筛选。 瑞孚迪（Revvity）的荧光探针活体成像技术弥补了同位素标记的不足，其无需放射性防护，显著降低 操作成本和时间，并能实现活体动态可视化追踪，成为抗体药早期研发阶段尤其是靶向性、药效动力学 及多靶点联检的快速、低成本初步筛选的理想工具。 同位素标记：成熟但成本与操作要求较高 1.成本因素：放射性同位素（如1?C、3H）本身价格较高，其合成标记过程需要特殊设备和资质认证， 叠加严格的安全防护、废物处理及合规管理成本，整体投入较大。 2.操作要求：全程需在符合P2级防护标准的放射性实验室操作，标记周期通常较长（2-4周），灵活性 受到一定限制。 瑞孚迪荧光染料：赋能高效初步体内分布研究 1.显著降本增效：荧光染料成本远低于同位素及相关处理费用，标记过程简便快捷，无需特殊防护 ...

Group 1 - The Hang Seng Index fell by 0.55%, down 131 points, closing at 23,695 points, while the Hang Seng Tech Index decreased by 0.66% [1] - The early trading volume in Hong Kong stocks reached HKD 1,076 million [1] - Robot-related stocks were active, with DCH Holdings (00179) rising nearly 6% and SUTENG (02498) increasing over 2% due to the upcoming CMG World Robot Competition [1] Group 2 - Eucan Vision Bio-B (01477) surged over 18% after OT-703 was approved for real-world research in Boao, Hainan [2] Group 3 - Smoore International (06969) rose over 5% as Glo Hilo is set to launch in Japan, with positive feedback from the trial market for heated non-combustible products [3] - Youjia Innovation (02431) increased over 5% after its L4 autonomous driving minibus received project designation, following a series of product showcases at the Shanghai Auto Show [3] Group 4 - Maanshan Iron & Steel (00323) saw a rise of over 7% as the steel industry showed improving performance in Q1, with institutions noting a marginal improvement in the sector's fundamentals [4] - InnoCare Pharma (02577) surged over 15% due to a partnership with NVIDIA for the next-generation 800V power architecture, drawing attention to third-generation semiconductors [4] Group 5 - Gu Ming (01364) increased by 4.5%, reaching a new high, with expectations of being included in the Hong Kong Stock Connect next month and a projected net increase of over 2,000 stores for the year [5] Group 6 - Dekang Agriculture and Animal Husbandry (02419) rose over 7%, with stock prices hitting a new high as institutions are optimistic about the company's valuation recovery potential [6] Group 7 - Gome Retail (06808) saw an early rise of nearly 7%, reporting a turnaround with a profit of RMB 410 million for the year, while Dehong Capital will promote the development of various store formats [7] - New Town Development (01030) fell over 3% amid reports of plans to issue guaranteed bonds domestically, aiming to raise RMB 1.5 to 2 billion [7] - Alibaba Health (00241) dropped over 4%, despite a year-on-year profit increase of over 62%, with analysts stating that profits did not meet expectations [7]

金十数据整理：每日港股市场要闻速递（4月22日 周二） 1. 中国联通(00762.HK)：2025年第一季度营收1033.5亿人民币，同比增涨3.9%；净利润59.3亿人民币。 同比增长5.6%。 2. 同程旅行(00780.HK)宣布与万达酒店发展就收购其全资子公司万达酒店管理（香港）有限公司达成协 议，交易对价约为人民币24.9亿元。 5. 药明生物(02269.HK)：杭州基地15000升原液生产线完成首个商业化项目PPQ生产。 3. 恒大汽车(00708.HK)：公司股票继续停牌，将持续发布季度发展更新，直至恢复或终止上市。 6. 融创中国(01918.HK)：与若干有代表性的债权人就境外债务重组方案达成一致。 4. 中国铁塔(00788.HK)：2025年第一季度，营业收入人民币247.71亿元，同比增长3.3%；归属公司股东 的利润30.24亿元，同比增长8.6%。 7. 呷哺呷哺(00520.HK)发布公告拟8900万元收购呷哺呷哺(中国)食品40%股权。 8. 顺丰控股(06936.HK)3月速运物流业务、供应链及国际业务合计收入236.61亿元，同比增长9.63%。 9. 招金矿业 (01 ...